IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

LA MURA, VINCENZO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 5.851
EU - Europa 5.382
NA - Nord America 5.095
SA - Sud America 718
AF - Africa 109
OC - Oceania 34
Continente sconosciuto - Info sul continente non disponibili 1
Totale 17.190
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.853
CN - Cina 2.021
SG - Singapore 1.454
GB - Regno Unito 1.420
IT - Italia 1.189
HK - Hong Kong 646
BR - Brasile 517
DE - Germania 493
RU - Federazione Russa 410
VN - Vietnam 401
SE - Svezia 378
BD - Bangladesh 373
FR - Francia 334
IN - India 277
ES - Italia 255
FI - Finlandia 179
JP - Giappone 167
NL - Olanda 140
IE - Irlanda 125
CA - Canada 120
KR - Corea 90
DK - Danimarca 88
MX - Messico 79
ID - Indonesia 75
TR - Turchia 72
AT - Austria 58
BE - Belgio 55
AR - Argentina 54
TW - Taiwan 44
CO - Colombia 43
PT - Portogallo 36
CH - Svizzera 34
GR - Grecia 31
IQ - Iraq 31
RO - Romania 31
AU - Australia 30
UA - Ucraina 28
PL - Polonia 27
CI - Costa d'Avorio 26
EC - Ecuador 25
SA - Arabia Saudita 25
PE - Perù 23
PH - Filippine 22
PK - Pakistan 22
ZA - Sudafrica 21
CL - Cile 20
TH - Thailandia 19
UY - Uruguay 16
RS - Serbia 15
UZ - Uzbekistan 15
MA - Marocco 14
DZ - Algeria 13
JO - Giordania 11
MY - Malesia 11
VE - Venezuela 11
IR - Iran 10
HR - Croazia 9
JM - Giamaica 9
TN - Tunisia 9
CZ - Repubblica Ceca 8
EG - Egitto 8
IL - Israele 8
KE - Kenya 8
PA - Panama 8
AZ - Azerbaigian 7
NP - Nepal 7
PY - Paraguay 7
QA - Qatar 7
AE - Emirati Arabi Uniti 6
CR - Costa Rica 6
KZ - Kazakistan 6
LU - Lussemburgo 6
NO - Norvegia 6
GT - Guatemala 5
BG - Bulgaria 4
HU - Ungheria 4
LT - Lituania 4
NZ - Nuova Zelanda 4
OM - Oman 4
SV - El Salvador 4
BY - Bielorussia 3
HN - Honduras 3
KH - Cambogia 3
MT - Malta 3
PS - Palestinian Territory 3
BO - Bolivia 2
DM - Dominica 2
DO - Repubblica Dominicana 2
ET - Etiopia 2
KW - Kuwait 2
LB - Libano 2
MD - Moldavia 2
MO - Macao, regione amministrativa speciale della Cina 2
SC - Seychelles 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
TZ - Tanzania 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BS - Bahamas 1
Totale 17.173
Salva come PNG Salva come JPEG
Città #
Southend 1.166
Singapore 841
Hong Kong 548
Ashburn 534
San Jose 360
Dallas 307
Milan 288
Beijing 274
Chandler 251
Seattle 194
Los Angeles 191
Council Bluffs 188
Frankfurt am Main 167
Princeton 140
Rome 136
Fairfield 134
Hefei 129
Ho Chi Minh City 129
Dublin 124
Wilmington 122
New York 121
Ann Arbor 120
Helsinki 116
Hanoi 110
Moscow 106
Guangzhou 104
Shanghai 103
Lauterbourg 96
Santa Clara 92
Bengaluru 89
Nanjing 83
Woodbridge 78
Dearborn 75
Redwood City 73
Houston 68
Tokyo 67
Barcelona 66
Buffalo 63
Des Moines 63
Chicago 58
Boardman 57
São Paulo 57
Jakarta 51
Cambridge 46
Jinan 42
Madrid 42
Bologna 41
Salford 40
Hangzhou 39
Phoenix 39
Munich 38
Roxbury 37
Grafing 36
Chongqing 35
Nuremberg 35
Cangzhou 34
Tianjin 33
Chengdu 32
Paris 32
Toronto 32
The Dalles 30
Vienna 30
Columbus 29
Rio de Janeiro 29
Xi'an 29
Zhengzhou 29
Brussels 28
Changsha 27
Abidjan 26
Seoul 26
London 25
Naples 25
San Diego 25
Wuhan 25
Fuzhou 23
Shenyang 23
Amsterdam 21
Hebei 21
Turin 21
Chennai 20
Florence 20
Istanbul 20
Shenzhen 20
Atlanta 19
Fremont 19
Lappeenranta 19
Mexico City 19
Taipei 19
Montreal 18
Bari 17
Brooklyn 17
Delhi 17
Hyderabad 17
Lima 17
Düsseldorf 16
Palermo 16
Rochester 16
Baghdad 15
Belo Horizonte 15
Bogotá 15
Totale 9.635
Salva come PNG Salva come JPEG
Nome #
Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis 886
Association Between Portosystemic Shunts and Increased Complications and Mortality in Patients With Cirrhosis 784
Porto-sinusoidal vascular liver disorder with portal hypertension: Natural History and Long-Term Outcome 740
Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension 496
Multimodality treatment of hepatocellular carcinoma : How field practice complies with international recommendations 469
A Prognostic Strategy Based on Stage of Cirrhosis and HVPG to Improve Risk Stratification After Variceal Bleeding 426
Performance of the model for end-stage liver disease score for mortality prediction and the potential role of etiology 380
Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis 340
Baveno VII – Renewing consensus in portal hypertension 337
The Role of Spleen and Liver Elastography and Color-Doppler Ultrasound in the Assessment of Transjugular Intrahepatic Portosystemic Shunt Function 278
Evaluation of three “beyond Baveno VI” criteria to safely spare endoscopies in compensated advanced chronic liver disease 261
Rational hemostatic management in cirrhosis: from old paradigms to new clinical challenges 250
Usefulness of fibrosis-4 (FIB-4) score and metabolic alterations in the prediction of SARS-CoV-2 severity 241
TACE with drug-eluting beads is effective for the maintenance of the milan-in status in patients with a small hepatocellular carcinoma 235
The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis 221
Coagulation, Microenvironment and Liver Fibrosis 221
AB0, von Willebrand factor/factor VIII and portal vein thrombosis in decompensated cirrhosis: Too late to unmask the culprit? 219
Pre-emptive TIPS in high-risk acute variceal bleeding. An updated and revised individual patient data meta-analysis 207
Determinants of esophageal varices bleeding in patients with advanced hepatocellular carcinoma treated with sorafenib 207
The impact of infection by multidrug resistant agents in patients with cirrhosis : A multicenter prospective study 206
Reappraisal of the conventional hemostasis tests as predictors of perioperative bleeding in the era of rebalanced hemostasis in cirrhosis 192
Harmful and Beneficial Effects of Anti-coagulants in Patients With Cirrhosis and Portal Vein Thrombosis 191
Intrahepatic vascular changes in non-alcoholic fatty liver disease : potential role of insulin-resistance and endothelial dysfunction 189
Reply 185
Sinusoidal endothelial dysfunction precedes inflammation and fibrosis in a model of NAFLD 180
Decompensation in Direct-Acting Antiviral Cured Hepatitis C Virus Compensated Patients With Clinically Significant Portal Hypertension: Too Rare to Warrant Universal Β-Blocker Therapy 180
Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma 179
Non-neoplastic portal vein thrombosis in HCV cirrhosis : the weight of inflammation on a fragile hemostatic balance 179
Deep vein thrombosis in COVID-19 patients in general wards: prevalence and association with clinical and laboratory variables 177
Resistance to thrombomodulin is associated with de novo portal vein thrombosis and low survival in patients with cirrhosis 175
Congenital extrahepatic portosystemic shunts (Abernethy malformation) : an international observational study 175
Prevalence, features and predictive factors of liver nodules in Fontan surgery patients: The VALDIG Fonliver prospective cohort 175
Clinical and genetic determinants of the fatty liver–coagulation balance interplay in individuals with metabolic dysfunction 169
Residual burden of liver disease after HCV clearance in hemophilia: a word of caution in the era of gene therapy 168
Simvastatin Prevents Liver Microthrombosis and Sepsis Induced Coagulopathy in a Rat Model of Endotoxemia 168
Hypercoagulability in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD): Causes and Consequences 167
Gene therapy in hemophilia: the dawn of a new era 165
Portal hypertension-like pattern in coronavirus disease 2019 acute respiratory distress syndrome 160
Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension 159
Impact of clonal hematopoiesis of indeterminate potential on hepatocellular carcinoma in individuals with steatotic liver disease 155
Treatment of spontaneous bacterial peritonitis 155
Injection drug use before and after liver transplantation: a retrospective multicenter analysis on incidence and outcome 155
The usefulness of D-dimer as a predictive marker for mortality in patients with COVID-19 hospitalized during the first wave in Italy 154
Hemostatic balance in patients with liver cirrhosis : report of a consensus conference 154
Effects of Early Placement of Transjugular Portosystemic Shunts in Patients With High-Risk Acute Variceal Bleeding: a Meta-analysis of Individual Patient Data 153
Cirrhosis and portal hypertension: the importance of risk stratification, the role of hepatic venous pressure gradient measurement 152
SOCS3 and IRS-1 gene expression differs between genotype 1 and genotype 2 hepatitis C virus-infected HepG2 cells 152
Use of non-selective beta blockers in cirrhosis: the evidence we need before closing (or not) the window 151
Comprehensive investigation of platelet function in patients with cirrhosis 142
Evolution of spontaneous portosystemic shunts over time and following aetiological intervention in patients with cirrhosis 139
Combined approach for embolization of otherwise unmanageable gastric varices 139
Right atrial pressure is not adequate to calculate portal pressure gradient in cirrhosis: a clinical-hemodynamic correlation study 138
Corrigendum to "Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin's lymphoma" [J Hepatol 49 (2008) 557-563] (DOI:10.1016/j.jhep.2008.06.025) 138
Occult hepatitis B virus infection in patients with non-Hodgkin lymphoma: the need for early diagnosis in anti-Hbc positive patients 136
Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin's lymphoma 133
Gene therapy for people with Haemophilia B: a proposed care delivery model in Italy 131
Coagulation and fibrosis: a potential non-negligible target of statins in chronic hepatitis 130
Prognosis of acute variceal bleeding : is being on beta-blockers an aggravating factor? A short-term survival analysis 130
Improving management of portal hypertension: the potential benefit of non-etiological therapies in cirrhosis 129
Clinical expression of insulin resistance in hepatitis C and B virus-related chronic hepatitis: differences and similarities 125
HBV and HCV infection in type 2 diabetes mellitus: a survey in three diabetes units in different Italian areas 125
Hepatitis C virus carriers with persistently normal ALT levels: biological peculiarities and update of the natural history of liver disease at 10 years 123
Therapeutic and clinical aspects of portal vein thrombosis in patients with cirrhosis 121
Bacterial translocation and nonselective β-blockers in portal hypertension: where we are, what we still need 120
Insulin resistance and liver microcirculation in a rat model of early NAFLD 119
Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension 116
Renin-angiotensin-aldosterone system in cirrhosis : There's room to try! 115
Portal Hypertension and Ascites: Patient-and Population-centered Clinical Practice Guidelines by the Italian Association for the Study of the Liver (AISF) 113
Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis: Insulin resistance and response to antiviral therapy 111
Liver sinusoidal endothelial dysfunction after LPS administration: a role for inducible-nitric oxide synthase 107
Role of Comorbidities in the General Management of Compensated Cirrhosis, Including Malnutrition 107
The management of liver disease in people with congenital bleeding disorders: guidance from European Association for Haemophilia and Allied Disorders, European Haemophilia Consortium, ISTH, and World Federation of Hemophilia 106
Patients whose first episode of bleeding occurs while taking a β-blocker have high long-term risks of rebleeding and death 105
Predicting survival in patients with ‘non-high-risk’ acute variceal bleeding receiving β-blockers+ligation to prevent re-bleeding 103
Lowering Portal Pressure Improves Outcomes of Patients With Cirrhosis, With or Without Ascites : a Meta-Analysis 103
Steatohepatitis is associated with diabetes and fibrosis in genotype 1b HCV-related chronic liver disease 102
Corticosteroid use to mitigate transaminitis-associated decline in FVIII levels following valoctocogene roxaparvovec gene therapy: clinical practice guidance 101
Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension 101
Antibiotic prophylaxis during bleeding for portal hypertension 101
Portal hypertension from molecular biology to clinical practice 101
Acute Portal Vein Thrombosis in SARS-CoV-2 Infection: A Case Report 100
Reply to the diagnostic conundrum of bacterial infections in cirrhotic patients 100
No correlation between fat liver accumulation and liver fibrosis in genotype 1B HCV related chronic liver disease 99
External validation of risk scores to predict in-hospital mortality in patients hospitalized due to coronavirus disease 2019 98
Liver Transplantation for Porto-sinusoidal Vascular Liver Disorder: Long-term Outcome 98
Liver-related aspects of valoctocogene roxaparvovec gene therapy for hemophilia A: expert guidance for clinical practice 98
HCV infection, HOMA index and sustained virological response: the step we need to take before moving forward 98
Prophylaxis of rebleeding in hepatocellular carcinoma: pushing the envelope or a real clinical benefit? 98
Statins in portal hypertension 95
Therapy of the refractory ascites : Total paracentesis vs. TIPS = Tratamiento de la ascitis refractaria: paracentesis total frente a derivación portosistémica intrahepática transyugular 95
Diagnosis of thrombophilia/prothrombotic conditions in patients with liver disease 91
Splanchnic vein thrombosis associated with SARS-CoV-2 infection: A VALDIG case–control study 90
Erratum to: HBV and HCV infection in type 2 diabetes mellitus: a survey in three diabetes units in different Italian areas (Acta Diabetologica, (2011), 48, 4, (337-343), 10.1007/s00592-011-0293-x) 90
The role of HBV occult infection in patients with non-hodgkin lymphoma: Prevalence and treatment options with nucleotide analogues 88
Effects of simvastatin administration on rodents with lipopolysaccharide-induced liver microvascular dysfunction 87
Metabolomics discloses potential biomarkers to predict the acute HVPG response to propranolol in patients with cirrhosis 85
Consensus Statements: Changing Scenarios: Prevention of Decompensation 84
Corrigendum to 'External validation of risk scores to predict in-hospital mortality in patients hospitalized due to coronavirus disease 2019' 80
Harmful and Beneficial Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis-Reply 78
Is non-alcoholic fatty liver disease a prothrombotic risk factor? 74
Totale 17.754
Salva come PNG Salva come JPEG
Categoria #
all - tutte 48.590
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 48.590
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021116 0 0 0 0 0 0 0 0 0 0 0 116
2021/20221.176 92 84 91 67 100 74 73 82 106 113 72 222
2022/20231.443 149 133 125 138 165 252 63 89 160 43 80 46
2023/20241.113 59 114 78 55 177 57 78 47 43 78 160 167
2024/20253.058 123 280 114 240 204 99 242 341 192 283 320 620
2025/20267.330 511 491 805 554 577 521 931 350 744 618 799 429
Totale 17.990